☆ 4.6 Letter

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

EUROPEAN RESPIRATORY JOURNAL (2021)

Get Full Text
Add to Collection

Journal

EUROPEAN RESPIRATORY JOURNAL
Volume 58, Issue 4, Pages -

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/13993003.00673-2021

Keywords

-

Categories

Respiratory System

Funding

  1. Theravance Biopharma Ireland Limited
  2. Theravance Biopharma US, Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.